Appili Therapeutics announces an offer of shares marketed on a daily basis
NOT FOR DISTRIBUTION TO UNITED STATES WIRE SERVICES OR FOR DISTRIBUTION IN THE UNITED STATES
HALIFAX, Nova Scotia, October 6, 2021– (BUSINESS WIRE) – Appili Therapeutics Inc. (TSX: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on the development of anti-infective drugs, today announced that it will undertake an offer (the “Offer”) of units (the “Units”), consisting of Class A Common Shares and Class A Common Share Warrants (the “Warrants”). The Offering must be made on a best-effort agency basis in each province of Canada (other than Quebec) by way of a prospectus supplement (the “Prospectus Supplement”) to the Company’s dated base shelf prospectus. of September 19, 2019 (as well as the Prospectus Supplement, the “Prospectus”). The number of units to be distributed, the price and composition of each unit, as well as the exercise price of each warrant will be determined in the context of the market, with final terms to be determined at the time of pricing. . The offering is expected to be made through a syndicate of agents led by Bloom Burton Securities Inc., and comprising iA Private Wealth Inc., Leede Jones Gable Inc., Research Capital Corporation and Richardson Wealth Ltd.
The Offer is subject to a number of conditions, including, without limitation, receipt of all regulatory approvals. The net proceeds of the Offering will be used primarily to fund research and development activities for the oral COVID-19 antiviral candidate Avigan® / Reeqonus ™ (favipiravir), including costs associated with the global Phase 3 trial d ‘Appili assessing Avigan / Reeqonus for the treatment of COVID-19 to moderate (PREventing Severe COVID-19; PRESECO). The net proceeds of the Offering will also be used to support business development initiatives aimed at expanding the Company’s program portfolio, as well as to fund the development costs of other Company product candidates, including the anti-fungal program. ATI-2307, and for working capital and corporate purposes. Details regarding the precise allocation of proceeds will be disclosed in the prospectus supplement.
The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “US Securities Act”), or any state securities law. and, therefore, may not be offered or sold in the United States (as that term is defined in Regulation S under the US Securities Act), except in accordance with the registration requirements of the US Securities Act and the applicable state securities requirements or by virtue of exemptions therefrom. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities of the Company in the United States.
About Appili Therapeutics
Appili Therapeutics is a purpose-built, portfolio-focused, people-focused infectious disease biopharmaceutical company to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of new therapies to prevent deaths and improve lives. As part of a global consortium, Appili is sponsoring advanced clinical trials evaluating the antiviral Avigan / Reeqonus for the treatment and prevention of COVID-19 around the world. The Company is also developing a diverse line of anti-infectives, including a broad-spectrum antifungal, a candidate vaccine to eliminate a serious biological weapon threat and two new antibiotic programs. Led by a proven management team, Appili is at the epicenter of the global infection control. For more information, visit www.AppiliTherapeutics.com.
This press release contains “forward-looking statements”, including with respect to the proposed terms of the offer and the proposed use of the product. Whenever possible, words such as “could”, “would”, “could”, “should”, “will”, “anticipate”, “believe”, “plan”, “‘wait”, “have the ‘intention’, ‘estimate’, ‘potential of’ and similar expressions have been used to identify these forward-looking statements. These forward-looking statements reflect the current expectations of the Company’s management for future growth, results of operations, performance and business prospects and opportunities and involve known and unknown risks, uncertainties and assumptions, including, without be limited to those listed in the annual information. form of the Company dated June 23, 2021 and other documents filed by the Company with the Canadian securities regulatory authorities (which can be viewed at www.sedar.com). If one or more of these risks or uncertainties materialize or if the assumptions underlying the forward-looking statements prove to be incorrect, actual results, performance or achievements may differ materially from those expressed or implied by the forward-looking statements contained in this press release. Press. These factors should be carefully considered and potential investors should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20211006005972/en/
APCO in the world
T: (646) 717 9915
E: [email protected]
Stéphane Paquette; Senior Director, Corporate Development
E: [email protected]